XML 47 R36.htm IDEA: XBRL DOCUMENT
v3.20.2

Note 2 - Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended
--- | --- | ---
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019
Revenues | [1] | $ 31,860 |  | $ 25,536 |  | $ 61,801 |  | $ 51,824 |
Consumables [Member] | Transferred at Point in Time [Member] |  |  |  |  |  |  |  |  |
Revenues |  | 13,486 |  | 11,572 |  | 27,747 |  | 24,329 |
Hardware and Software [Member] | Transferred at Point in Time [Member] |  |  |  |  |  |  |  |  |
Revenues |  | 11,321 |  | 7,892 |  | 20,981 |  | 16,547 |
Service [Member] | Transferred at Point in Time [Member] |  |  |  |  |  |  |  |  |
Revenues |  | 4,353 |  | 3,704 |  | 7,768 |  | 6,598 |
Service [Member] | Transferred over Time [Member] |  |  |  |  |  |  |  |  |
Revenues |  | 2,700 |  | 2,368 |  | 5,305 |  | 4,350 |
Corporate, Non-Segment [Member] |  |  |  |  |  |  |  |  |
Revenues |  | 0 |  | 896 | [1] |  |  | 2,213 | [1]
Corporate, Non-Segment [Member] | Consumables [Member] | Transferred at Point in Time [Member] |  |  |  |  |  |  |  |  |
Revenues |  | 0 |  | 877 |  |  |  | 2,186 |
Corporate, Non-Segment [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] |  |  |  |  |  |  |  |  |
Revenues |  | 0 |  | 0 |  |  |  |  |
Corporate, Non-Segment [Member] | Service [Member] | Transferred at Point in Time [Member] |  |  |  |  |  |  |  |  |
Revenues |  | 0 |  | 19 |  |  |  | 27 |
Corporate, Non-Segment [Member] | Service [Member] | Transferred over Time [Member] |  |  |  |  |  |  |  |  |
Revenues |  | 0 |  | 0 |  |  |  |  |
Sterilization and Disinfection Control [Member] | Operating Segments [Member] |  |  |  |  |  |  |  |  |
Revenues | [1] | 11,552 |  | 12,094 |  | 24,619 |  | 24,204 |
Sterilization and Disinfection Control [Member] | Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] |  |  |  |  |  |  |  |  |
Revenues |  | 9,518 |  | 10,122 |  | 21,002 |  | 20,539 |
Sterilization and Disinfection Control [Member] | Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] |  |  |  |  |  |  |  |  |
Revenues |  | 108 |  | 148 |  | 237 |  | 334 |
Sterilization and Disinfection Control [Member] | Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] |  |  |  |  |  |  |  |  |
Revenues |  | 706 |  | 641 |  | 956 |  | 941 |
Sterilization and Disinfection Control [Member] | Operating Segments [Member] | Service [Member] | Transferred over Time [Member] |  |  |  |  |  |  |  |  |
Revenues |  | 1,220 |  | 1,183 |  | 2,424 |  | 2,390 |
Instruments [Member] | Operating Segments [Member] |  |  |  |  |  |  |  |  |
Revenues | [1] | 7,558 |  | 8,960 |  | 15,238 |  | 18,504 |
Instruments [Member] | Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] |  |  |  |  |  |  |  |  |
Revenues |  | 715 |  | 563 |  | 1,523 |  | 1,583 |
Instruments [Member] | Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] |  |  |  |  |  |  |  |  |
Revenues |  | 4,815 |  | 5,923 |  | 9,835 |  | 12,401 |
Instruments [Member] | Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] |  |  |  |  |  |  |  |  |
Revenues |  | 2,028 |  | 2,474 |  | 3,880 |  | 4,520 |
Instruments [Member] | Operating Segments [Member] | Service [Member] | Transferred over Time [Member] |  |  |  |  |  |  |  |  |
Revenues |  | 0 |  | 0 |  |  |  |  |
Biopharmaceutical Development [Member] | Operating Segments [Member] |  |  |  |  |  |  |  |  |
Revenues |  | 9,131 | [1] | 0 |  | 15,080 | [1] |  |
Biopharmaceutical Development [Member] | Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] |  |  |  |  |  |  |  |  |
Revenues |  | 3,238 |  | 0 |  | 5,177 |  |  |
Biopharmaceutical Development [Member] | Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] |  |  |  |  |  |  |  |  |
Revenues |  | 4,191 |  | 0 |  | 6,747 |  |  |
Biopharmaceutical Development [Member] | Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] |  |  |  |  |  |  |  |  |
Revenues |  | 1,005 |  | 0 |  | 1,787 |  |  |
Biopharmaceutical Development [Member] | Operating Segments [Member] | Service [Member] | Transferred over Time [Member] |  |  |  |  |  |  |  |  |
Revenues |  | 697 |  | 0 |  | 1,369 |  |  |
Continuous Monitoring [Member] | Operating Segments [Member] |  |  |  |  |  |  |  |  |
Revenues |  | 3,619 |  | 3,586 |  | 6,864 |  | 6,903 |
Continuous Monitoring [Member] | Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] |  |  |  |  |  |  |  |  |
Revenues |  | 15 |  | 10 |  | 45 |  | 21 |
Continuous Monitoring [Member] | Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] |  |  |  |  |  |  |  |  |
Revenues |  | 2,207 |  | 1,821 |  | 4,162 |  | 3,812 |
Continuous Monitoring [Member] | Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] |  |  |  |  |  |  |  |  |
Revenues |  | 614 |  | 570 |  | 1,145 |  | 1,110 |
Continuous Monitoring [Member] | Operating Segments [Member] | Service [Member] | Transferred over Time [Member] |  |  |  |  |  |  |  |  |
Revenues |  | $ 783 |  | $ 1,185 |  | $ 1,512 |  | $ 1,960 |
[1] | Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=mlab_ConsumablesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mlab_HardwareAndSoftwareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ServiceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mlab_SterilizationAndDisinfectionControlMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mlab_InstrumentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mlab_BiopharmaceuticalDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mlab_ContinuousMonitoringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |